Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psychedelics and Psychedelic-Assisted Psychotherapy
Collin Reiff, Elon E. Richman, Charles B. Nemeroff, et al.
American Journal of Psychiatry (2020) Vol. 177, Iss. 5, pp. 391-410
Closed Access | Times Cited: 446

Showing 1-25 of 446 citing articles:

The Critical Relationship Between Anxiety and Depression
Ned H. Kalin
American Journal of Psychiatry (2020) Vol. 177, Iss. 5, pp. 365-367
Open Access | Times Cited: 451
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 2, pp. 151-158
Open Access | Times Cited: 296
Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
Roger S. McIntyre, Mohammad Alsuwaidan, Bernhard T. Baune, et al.
World Psychiatry (2023) Vol. 22, Iss. 3, pp. 394-412
Open Access | Times Cited: 246
Structure-based discovery of nonhallucinogenic psychedelic analogs
Dongmei Cao, Jing Yu, Huan Wang, et al.
Science (2022) Vol. 375, Iss. 6579, pp. 403-411
Closed Access | Times Cited: 211
Towards an understanding of psychedelic-induced neuroplasticity
Abigail E. Calder, Gregor Hasler
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 104-112
Open Access | Times Cited: 173
The role of dissociation in ketamine’s antidepressant effects
Elizabeth D. Ballard, Carlos A. Zarate
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 140
The promises and perils of psychedelic pharmacology for psychiatry
Tristan McClure‐Begley, Bryan L. Roth
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 6, pp. 463-473
Closed Access | Times Cited: 139
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Joost J. Breeksema, Bouwe Kuin, Jeanine Kamphuis, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 10, pp. 1100-1117
Open Access | Times Cited: 126
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
Nicole Leite Galvão‐Coelho, Wolfgang Marx, Maria Gonzalez, et al.
Psychopharmacology (2021) Vol. 238, Iss. 2, pp. 341-354
Open Access | Times Cited: 117
Preparing for the Bursting of the Psychedelic Hype Bubble
David B. Yaden, James B. Potash, Roland R. Griffiths
JAMA Psychiatry (2022) Vol. 79, Iss. 10, pp. 943-943
Closed Access | Times Cited: 91
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life
Guy M. Goodwin, Scott T. Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders (2023) Vol. 327, pp. 120-127
Open Access | Times Cited: 91
Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics
Otto Simonsson, Peter S. Hendricks, Richard Chambers, et al.
Journal of Affective Disorders (2023) Vol. 326, pp. 105-110
Open Access | Times Cited: 69
Accelerated TMS - moving quickly into the future of depression treatment
Sanne J.H. van Rooij, Amanda R. Arulpragasam, William M. McDonald, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 128-137
Open Access | Times Cited: 42
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
Sipan Haikazian, David Chen‐Li, Danica E. Johnson, et al.
Psychiatry Research (2023) Vol. 329, pp. 115531-115531
Closed Access | Times Cited: 42
Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
Joshua D. Rosenblat, Shakila Meshkat, Zoe Doyle, et al.
Med (2024) Vol. 5, Iss. 3, pp. 190-200.e5
Closed Access | Times Cited: 28
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
Yuan Yao, Dan Guo, Tangsheng Lu, et al.
Psychiatry Research (2024) Vol. 335, pp. 115886-115886
Closed Access | Times Cited: 23
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
Adam W. Levin, Rafael Lancelotta, Nathan D. Sepeda, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0300501-e0300501
Open Access | Times Cited: 22
Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects
Helena D. Aicher, Michael J. Mueller, Dario A. Dornbierer, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 16
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 15
MDMA and MDMA-Assisted Therapy
Aaron Wolfgang, Gregory A. Fonzo, Joshua C. Gray, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 79-103
Closed Access | Times Cited: 3
Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor
Isabella Sutherland, Ming‐Fen Ho, Paul E. Croarkin
Journal of Child and Adolescent Psychopharmacology (2025)
Closed Access | Times Cited: 3
The State of Our Understanding of the Pathophysiology and Optimal Treatment of Depression: Glass Half Full or Half Empty?
Charles B. Nemeroff
American Journal of Psychiatry (2020) Vol. 177, Iss. 8, pp. 671-685
Closed Access | Times Cited: 125
Depression: Biological markers and treatment
Gordana Nedić Erjavec, Marina Šagud, Matea Nikolac Perković, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 105, pp. 110139-110139
Closed Access | Times Cited: 84
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Bashkim Kadriu, Maximillian Greenwald, Ioline D. Henter, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 1, pp. 8-21
Open Access | Times Cited: 81
Psychedelic medicine: safety and ethical concerns
B. Anderson, Alicia Danforth, Charles S. Grob
The Lancet Psychiatry (2020) Vol. 7, Iss. 10, pp. 829-830
Open Access | Times Cited: 80
Page 1 - Next Page

Scroll to top